CTOs on the Move

Lifemark Health Group

www.lifemarkhealthgroup.ca

 
Lifemark Health Group is a diversified healthcare company in business since 1998 and has grown by acquisition over the past 13 years to include over 200 facilities across Canada.
  • Number of Employees: 1K-5K
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Vetoquinol N.-A. Inc

Vetoquinol N.-A. Inc is a Lavaltrie, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The South Carolina Neurological Clinic, PA

The South Carolina Neurological Clinic, PA is a Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

American Association of Nuerological Surgeons

American Association of Nuerological Surgeons is a Rolling Meadows, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DiscoveRx

DiscoveRx is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Fremont, CA. To find more information about DiscoveRx, please visit www.discoverx.com

Bionor Pharma

Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.